Clinical Trial Update: Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study assessed the safety of topical mesenchymal stromal cell secretome for ocular surface disease. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Defect
• Corneal Epithelial Defect
• Ocular Surface Disease

Drugs mentioned

• Topical mesenchymal stromal cell secretome

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Mesenchymal Stromal Cells, Cornea | EARLY_Phase 1 | Status: COMPLETED